Research programme: antisense oligonucleotide therapy - Splisense
Latest Information Update: 08 Sep 2021
At a glance
- Originator SpliSense
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cystic fibrosis
Most Recent Events
- 27 Aug 2021 Early research in Cystic fibrosis in Israel (Inhalation) prior to August 2021 (Splisense pipeline, August 2021)